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Abstract
Background: Multiple case definitions are in use to identify chronic fatigue syndrome (CFS). Even when using the
same definition, methods used to apply definitional criteria may affect results. The Centers for Disease Control
and Prevention (CDC) conducted two population-based studies estimating CFS prevalence using the 1994 case
definition; one relied on direct questions for criteria of fatigue, functional impairment and symptoms (1997 Wichita;
Method 1), and the other used subscale score thresholds of standardized questionnaires for criteria (2004 Georgia;
Method 2). Compared to previous reports the 2004 CFS prevalence estimate was higher, raising questions about
whether changes in the method of operationalizing affected this and illness characteristics.
Methods: The follow-up of the Georgia cohort allowed direct comparison of both methods of applying the 1994
case definition. Of 1961 participants (53 % of eligible) who completed the detailed telephone interview, 919 (47 %)
were eligible for and 751 (81 %) underwent clinical evaluation including medical/psychiatric evaluations. Data from
the 499 individuals with complete data and without exclusionary conditions was available for this analysis.
Results: A total of 86 participants were classified as CFS by one or both methods; 44 cases identified by both
methods, 15 only identified by Method 1, and 27 only identified by Method 2 (Kappa 0.63; 95 % confidence interval
[CI]: 0.53, 0.73 and concordance 91.59 %). The CFS group identified by both methods were more fatigued, had
worse functioning, and more symptoms than those identified by only one method. Moderate to severe depression
was noted in only one individual who was classified as CFS by both methods. When comparing the CFS groups
identified by only one method, those only identified by Method 2 were either similar to or more severely affected
in fatigue, function, and symptoms than those only identified by Method 1.
Conclusions: The two methods demonstrated substantial concordance. While Method 2 classified more participants
as CFS, there was no indication that they were less severely ill or more depressed. The classification differences do not
fully explain the prevalence increase noted in the 2004 Georgia study. Use of standardized instruments for the major
CFS domains provides advantages for disease stratification and comparing CFS patients to other illnesses.
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Background
Chronic fatigue syndrome (CFS) is a debilitating multi-
system illness that compromises occupational, educa-
tional, social, or personal activities and is accompanied
by fatigue persisting longer than 6 months, as well as a
variety of symptoms that may include significant col-
lapse or relapse after exertion (post-exertional malaise),
sleep problems, cognitive impairment, dizziness, muscle
aches and pains, tender lymph nodes, and headaches.
Many case definitions for CFS, as well as for myalgic en-
cephalomyelitis (ME) or ME/CFS, have been proposed
and debated in the literature. Those in use include the
1994 case definition [1], the 2003 Canadian case defin-
ition [2], the 2010 revised Canadian case definition [3],
and the 2011 International Consensus Criteria [4].
Concerns about case definitions used for epidemiologic
studies, clinical diagnosis, and research are not unique
to CFS, and in fact are common in such diverse illnesses
as acute coronary heart disease [5], chronic kidney
disease [6], interstitial cystitis [7], periodontitis [8] and
toxic shock syndrome [9], to give a few examples.
While surveys indicate that healthcare providers are
aware of ME/CFS [10], other reports document the diffi-
culties that physicians have in recognizing an illness that
lacks a diagnostic test, as well as the delays and frustra-
tions that patients experience in being diagnosed [11].
With the aim of improved clinical care for ME/CFS, the
Institute of Medicine (IOM) recently conducted an in-
depth review of the evidence for diagnostic criteria for
ME/CFS, considering input from patients as well as the
physicians and advocates caring for them. Their report
confirms the serious nature of this illness and provides
guidance on clinical criteria for ME/CFS to make it easier
for clinicians to recognize and diagnose patients in a timely
manner (http://www.iom.edu/Reports/2015/ME-CFS.aspx).
In recognition of the many gaps in knowledge about
this illness and need for more research, the IOM report
further recommends reexamining diagnostic criteria in
no more than 5 years.
Research on nearly every aspect of ME/CFS such as
prevalence of illness, risk factors, disease course, eti-
ology, and response to therapy requires studying well-
defined patients or patient subgroups. Case definitions
are used to identify patients but have limitations in their
ability to accurately and reproducibly classify patients. In
addition, variations in study methods extend beyond the
case definition. The study population (e.g., clinic versus
community), method of recruitment and screening, ex-
tent of medical and psychiatric evaluation to rule out
other illness, matching criteria for case–control compar-
isons, and questionnaires/instruments used to ascertain
information about participants’ health all have the po-
tential to affect results [12–16]. For chronic illnesses
such as ME/CFS, duration of illness, medications, and
co-morbid conditions all contribute to heterogeneity. A
recent publication suggested that developing consensus
on data elements about CFS patients and their illness to
be included in research publications could help investi-
gators compare findings across different studies [17].
The case definition is clearly one of these elements, but
it is insufficient to simply state which case definition was
used without describing how it was operationalized.
CDC has conducted two population-based longitu-
dinal studies of CFS [18, 19]; both used random-digit-
dialing to select and survey households, included clinical
and laboratory testing to identify exclusionary condi-
tions, and based classification on the 1994 case defin-
ition [1]. However, there were two significant differences
in the studies: 1) the screening criteria for eligibility to
attend the clinical evaluation (both household and indi-
vidual screening interviews and eligibility criteria), and
2) the method of applying the case definition (question-
naires and case definition algorithms). These differences
are highlighted briefly, omitting details that can be found
in the original reports [18, 19]. The longitudinal study in
Sedgewick County Kansas, initiated in 1997 (1997 Wich-
ita), required respondents to endorse fatigue, and identi-
fied symptoms required for the case definition by asking
respondents whether or not they experienced each.
From this longitudinal study, we observed that a sub-
stantial portion of subjects meeting CFS criteria during
follow-up were not incident cases, but prevalent cases
that were not identified in initial surveillance cycles.
This largely occurred because fatigue was used as the
sole screening criteria during the household informant
interview. Households with an individual whose illness
was not perceived as involving fatigue during the inter-
view, either by the household informant or themselves,
were not selected or evaluated at the clinic. Therefore,
when we initiated the Georgia surveillance study in 2004
(2004 Georgia), we expanded the screening interviews to
the four major core symptoms of the syndrome: fatigue,
cognitive impairment, unrefreshing sleep, and pain. Fur-
thermore, following published recommendations, stan-
dardized questionnaires were used to measure the three
domains of illness required by the 1994 case definition
(fatigue, functional impairment, and symptoms) [14, 20].
These changes in the method of applying the 1994
case definition resulted in concerns about whether the
cases identified in the Georgia study truly had CFS, or if
the expanded screening criteria and reliance on ques-
tionnaires resulted in misclassification of persons with
psychiatric co-morbidities or inclusion of relatively mild
or non-specific fatiguing illness [21]. We used the data
from the follow-up (GA-T1) of the baseline Georgia co-
hort to apply the 1994 case definition using both the
1997 Wichita [18] and the 2004 Georgia [19] methods.
The objectives of this analysis are to directly compare
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the extent of agreement in case ascertainment and to
compare the illness characteristics of participants in
GA-T1 classified as CFS by the two methods.
Methods
Data source and study sample
Data came from the follow-up of a population-based
study of CFS in Georgia (GA-T1). The CDC Institutional
Review Board approved the study and all participants
provided informed consent.
Details of the baseline study conducted in 2004–2005
have been published [19, 22]. In brief, a random-digit-
dialing screening telephone interview identified respon-
dents who were ill 6 months or longer with one or more
of the CFS illness domains of fatigue, sleep, pain, or cog-
nition, and those who were well. Eligible respondents
were randomly selected for a detailed telephone inter-
view to identify exclusionary conditions and features of
CFS. After the detailed interview, all participants who
appeared to meet criteria for CFS (CFS-like), non-ill
controls (matched to CFS-like on age, sex, race, and
residence), and randomly selected participants (number
equal to the total of CFS-like and controls) from an
intermediate group (ill but not meeting all CFS-like cri-
teria) were invited for clinical evaluation. The clinical
visit was completed by 783 persons and included de-
tailed medical history, physical examination, laboratory
tests, psychiatric evaluation, and questionnaires to meas-
ure functional impairment, fatigue, and other symptoms
(Fig. 1).
Those eligible for the follow-up study (GA-T1) con-
ducted during 2007–2009 (schematic diagram in Fig. 1) in-
cluded the 3730 individuals from the phone-interviewed
cohort in the baseline study (66 %) who did not have
exclusionary conditions (i.e., all 681 participants seen in
clinic without permanent exclusions and 3049 who only
completed the baseline detailed telephone interview). Of
those eligible, 1961 (53 %) completed the follow-up de-
tailed telephone interview. Respondents invited to the
follow-up clinical evaluation included all those eligible at
baseline (including all seen in clinic who had no perman-
ent exclusions) and newly identified CFS-like respondents
along with well subjects matched on residence (metropol-
itan, urban, rural), sex, race/ethnicity, and age (within
3 years). Of the 1961 individuals who completed the
follow-up detailed telephone interview, 919 (47 %) were eli-
gible for the 1-day clinical evaluation and 751 (81 %) com-
pleted this evaluation.
The clinical evaluation included a detailed medical his-
tory, physical examination, laboratory tests, and the
Structured Clinical Interview for DSM Disorders (SCID)
to identify exclusionary medical and psychiatric condi-
tions. All clinic participants completed the Zung self-
rating depression scale (SDS) that includes 20 items
measuring core symptoms of major depression during
the past week [23]. Each item was scored on a Likert
scale ranging from 1 to 4. A total score was derived by
summing the individual item scores, and ranges from 20
to 80. A score >60 is considered moderate to severe de-
pression. Of the 751 participants who completed the
GA-T1 clinical evaluation, 249 (39 %) were identified as
having one or more exclusionary medical and/or psychi-
atric conditions. Additionally, the exclusionary status of
three individuals could not be determined due to incom-
plete lab results. These 252 individuals were removed from
the current analysis, and the remaining 499 individuals
without exclusionary conditions form the basis of this
report.
Fig. 1 Schematic diagram for GA-T1 study conducted during 2007–2009
Unger et al. Population Health Metrics  (2016) 14:5 Page 3 of 10
Methods of applying the 1994 CFS case definition
The 1994 CFS case definition specifies three major di-
mensions of CFS: fatigue, functional impairment, and
eight accompanying symptoms (e.g., post-exertional mal-
aise, impaired memory or concentration, sore throat,
tender cervical or axillary lymph nodes, muscle pain,
multi-joint pain, new headaches, unrefreshing sleep) [1].
Fatigue, functional impairment, and at least 4 of the
eight symptoms need to be present for at least 6 months.
We evaluated the same three dimensions on all study
participants using two methods. Method 1 used direct
questions to address each feature of the case definition
as in the 1997 Wichita study [18]. Method 2 used ques-
tionnaires with the subscale thresholds used in the 2004
Georgia study (see Table 1) [19].
Method 1: the 1997 Wichita method
Fatigue ≥ 6 months duration, not relieved by rest.
During the detailed telephone interview, we asked par-
ticipants questions about the occurrence, duration, and
frequency of their fatigue (severe fatigue, extreme tired-
ness, or exhaustion). If participants responded “yes” to
fatigue in the past month, they were asked whether they
had this fatigue persisting or relapsing for 6 months or
longer (response choices: “yes” or “no”). If yes, we asked
whether rest made their fatigue a lot better (response
choices: “yes” or “no”); participants responding “yes”
were asked how often this fatigue was relieved by rest
(response choices: “all of the time”, “most of the time”,
“some of the time”, “a little of the time”, or “hardly
ever”). Participants were considered to meet fatigue
criterion if they reported fatigue persisting or relapsing
for 6 months or longer and responded “no” to fatigue
made a lot better by rest or fatigue relieved by rest “some
of the time”, “a little of the time”, or “hardly ever”.
Functional impairment All participants responding
“yes” to severe fatigue, extreme tiredness, or exhaustion
for 1 month or longer in the screening interview were
questioned during the detailed telephone interview to
determine functional impairment, defined as substantial
reduction in pre-illness level of occupational, educa-
tional, social, or personal activities. Participants were
asked about each area of functioning in three separate
questions (response choices: “yes”, “no”, “don’t know”,
“not applicable”, or “refused”). Participants were consid-
ered to meet the functional impairment criterion if they
responded “yes” to any of the following three questions:
(i) “Has this severe fatigue, extreme tiredness, or
exhaustion substantially limited your ability to do
your usual job or occupation?”
(ii) “Has this severe fatigue, extreme tiredness, or
exhaustion substantially limited your ability to do
your usual educational activities?”
(iii) “Has this severe fatigue, extreme tiredness, or
exhaustion substantially limited your social, leisure,
or recreational activities?”
Case defining symptoms We asked all participants
about their experience during the past month with each
of the eight symptoms specified in the 1994 case defin-
ition, e.g., “during the past month how often have you
had a sore throat?” with response choices “all of the
Table 1 Brief comparison of methods of applying the 1994 case definition of CFS (see text for details)
Method 1 – 1997 Wichita method Method 2 – 2004 Georgia method
Fatigue Telephone interview –
“Severe fatigue, extreme tiredness, or exhaustion”
- Duration 6 months or longer “Yes”
AND
- Rest makes fatigue a lot better
“No” OR “Yes” – Some of the time, a little of the
time, or hardly ever




Functional Impairment Telephone interview – “Yes” to one:
“Has this severe fatigue, extreme tiredness or
exhaustion substantially limited …
…your ability to do your usual job or occupation?
…your ability to do your usual educational activities









4 of 8 Case Defining Symptomsa During the past month how often have you had
< SYMPTOM> − “All the time” OR “Most of the
time”
AND
Was < SYMPTOM > bothering you 6 months or
longer – “Yes”
CDC Symptom Inventory
<SYMPTOM > frequency X intensity scores summed
for 8 case defining symptoms≥25 and scores for at
least 4 symptoms
Abbreviations: MFI-20 multidimensional fatigue inventory-20 questions, SF-36 medical outcomes survey short form-36 questions
aCFS case defining symptoms: post-exertional malaise, impaired memory or concentration, sore throat, tender cervical or axillary lymph nodes, muscle
pain, multi-joint pain, new headaches, unrefreshing sleep
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time,” “most of the time”, “some of the time”, “rarely”, or
“never”. Those responding “all” or “most of the time” for
any symptom were asked if the symptom was bothering
them 6 months or longer (response choices: “yes”, “no”,
“don’t know”, “not applicable”, or “refused”). A symptom
that was present “all” or “most of the time” and “yes” ≥6
months duration was considered to be endorsed. Partic-
ipants endorsing ≥4 symptoms were considered to meet
the symptom criterion.
Method 2: the 2004 Georgia method
Fatigue We assessed fatigue severity with the 20-item
Multidimensional Fatigue Inventory (MFI-20) adminis-
tered at the clinic [24, 25]. Higher scores in each MFI-20
subscale (range: 4 to 20) indicate more severe fatigue.
Those scoring ≥13 in the General Fatigue subscale
or ≥10 in the Reduced Activity subscale were considered
to meet the fatigue criterion. As population normative
values were not available at that time, cut-off was based
on the median scores from the non-fatigue well group in
the Wichita clinical study. Subsequently normative
values for a German population were published. The
selected subscale thresholds are higher than the 75th
percentile for males and females age 40–59 (10 and 11,
respectively for General Fatigue; 9 and 11, respectively
for Reduced Activity subscale) [26].
Functional impairment We assessed functional impair-
ment using the Medical Outcomes Survey Short Form-36
version 2 (SF-36 v2) administered at the clinic [27, 28].
Lower SF-36 subscale scores indicate worse functioning
(range: 0 to 100). The item responses for the subscales of
Role Physical and Role Emotional were collapsed into yes/
no for consistency with SF-36 v1 used in previous studies
[19, 20]. Those scoring below the 25th percentile of pub-
lished data for the 1998 US general population in any one
of four subscales [Physical Function (≤70), Role Physical
(≤50), Social Function (≤75), Role Emotional (≤66.7)] were
considered to meet the functional impairment criterion.
Case defining symptoms We assessed symptoms using
the CDC Symptom Inventory (SI) administered at the
clinic [29]. The questionnaire (provided in supplemen-
tary material) asks about the frequency and intensity of
symptoms experienced during the past month (the eight
CFS-defining symptoms, as well as an additional 11
illness symptoms). The revised version of the CDC SI
used in this study provided a five-point scale for fre-
quency and intensity of 19 symptoms. Participants were
asked to report the frequency (1 = “a little of the time”,
2 = “some of the time”, 3 = “a good bit of the time”, 4
= “most of the time”, 5 = “all of the time”) and inten-
sity or severity (1 = “very mild”, 2 = “mild”, 3 = “mod-
erate”, 4 = “severe”, 5 = “very severe”). For consistency
with the original version of CDC SI [30], we collapsed the
responses into the following categories: the frequency
response value (1 = “a little of the time”, 2 = “some of
the time,” 3 = “a good bit of the time” or “most of the
time”, 4 = “all of the time”) by the severity or intensity
response value (1 = “very mild” or “mild”, 2.5 = “mod-
erate”, 4 = “severe” or “very severe”). Symptoms that
had been present less than 6 months were scored 0.
For symptoms that had been present for at least
6 months, individual symptom scores were calculated
by multiplying the frequency value by the intensity
value. The CFS symptom summary score was calcu-
lated as the sum of the eight CFS individual symptom
scores. Participants with at least four of the eight CFS
symptoms for at least 6 months and a CFS symptom
summary score ≥25 were considered to meet the
symptom criterion [29].
Statistical analysis
We calculated the concordance percentage and Kappa
coefficient to examine the agreement between case as-
certainment using each method of applying the 1994
CFS case definition: Method 1 (M1; 1997 Wichita) and
Method 2 (M2; 2004 Georgia). We examined the fatigue,
functional impairment, and symptom profiles of the CFS
cases identified with both methods (M1/M2), compared
to the CFS cases identified only with Method 2 (only
M2) and the CFS cases identified only with the Method
1 (only M1). General linear models were used to exam-
ine the group effect and ad-hoc comparisons across
three groups (M1/M2, only M1, and only M2) were also
performed with Bonferroni correction for the p-value
adjustment. All tests of significance were two-sided with
the alpha level set at 0.05.
Results
Table 2 summarizes the demographics of the study sam-
ple, as well as duration and onset of fatiguing illness for
those classified as CFS. The majority were female
(73.55 %), white (78.96 %), lived in a rural or urban area
(81.36 %), or had at least some college education
(80.16 %). The mean age of participants was 47.61 years.
Of the 499 subjects without exclusionary conditions, 86
were classified as CFS by one or both methods: 59 with
Method 1 (M1), and 71 with Method 2 (M2). There
were no statistically significant differences in the propor-
tion of females, mean duration of fatigue, or proportion
with sudden onset among CFS cases classified by the two
methods. As shown in Table 3, the Kappa statistic for
agreement was substantial (0.63; 95 % CI: 0.53, 0.73) and
the overall concordance of classification for the two
methods was 91.59 %. There were 44 cases identified
by both methods (M1/M2), 15 cases only identified
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by Method 1 (only M1), and 27 cases only identified
by Method 2 (only M2).
Table 4 shows the fatigue, functional impairment, and
symptom profile as measured by MFI-20, SF-36 and
CDC SI as well as depression scores for participants
classified as CFS, divided into three non-overlapping
groups (M1/M2, only M1, and only M2). Participants
identified with both methods (M1/M2) were in general
more fatigued, had more functional impairment, more
CFS symptoms, higher symptom scores and higher Zung
scores compared to those identified by only one method.
Comparing characteristics of the CFS cases identified by
only one of the two methods highlights differences that
could be missed if comparisons of M1 and M2 included
those identified by both methods. There were no statisti-
cally significant differences between the groups identi-
fied only by Method 1 (only M1) and only by Method 2
(only M2) on the MFI-20 subscales except for the
General Fatigue subscale, where the only M2 group was
more severe (difference of 2.39 points). In four of the
eight SF-36 subscales, individuals in the only M2 group
had significantly more functional impairment than the
only M1 group (Physical Functioning, Role Physical,
Social Functioning, and Bodily Pain; range of differences
13.53 to 29.00). Those in the only M2 group also had
significantly higher symptom scores than the only M1
group (score difference 17.12). Mean SF-36 scores for
Vitality and Mental Health were not significantly differ-
ent between the only M1 and only M2 groups, but the




1994 Case Definition Method
Method 1 (n=59) Method 2 (n = 71)
Characteristicsa [values are n (%)
Age in Yrs, Mean (SD) 47.61 (9.84) 46.76 (9.82) 47.93 (9.90)
Sex
Female 367 (73.55) 49 (83.05) 65 (91.55)
Male 132 (26.45) 10 (16.95) 6 (8.45)
Race
Black 98 (19.64) 8 (13.56) 12 (16.90)
White 394 (78.96) 48 (81.36) 56 (78.87)
All Others 7 (1.40) 3 (5.08) 3 (4.23)
Geographic Area
Metropolitan 93 (18.64) 7 (11.86) 8 (11.27)
Urban 161 (32.26) 29 (49.15) 39 (54.93)
Rural 245 (49.10) 23 (38.98) 24 (33.80)
Married 351(70.62) 38 (64.41) 46(64.79)
Education
≤ High School 99 (19.84) 15 (25.42) 17 (23.94)
Some College 165 (33.07) 22 (37.29) 27 (38.03)
≥ College 233 (46.69) 22 (37.29) 27 (38.03)
Type of onset
Sudden n/a 10 (16.95) 11 (15.49)
Gradual n/a 46 (77.97) 36 (50.70)
Not known n/a 3 (5.08) 24 (33.80)
Duration Fatigue in Yrs, Mean (SD) n/a 12.13(8.92) 12.26 (9.87)
n/a not applicable
aValues are n (%) unless otherwise indicated
Table 3 Comparison of CFS Case Ascertainment using Two
Methods of Applying the 1994 Case Definition (n=499)
Method 1
CFS Non-CFS
Method 2 CFS 44 27
Non-CFS 15 413
Kappa= 0.63, 95 % CI= 0.53 - 0.73.
Concordance= 91.59 %
Discordance= 8.41 %
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M1/M2 group scores in Vitality and Mental Health
(20.80, 55.55) were significantly lower than the only M1
group (36.33, 75.73), indicating more severe impairment.
While not statistically significant, the proportion of
individuals who experienced post-exertional malaise
6 months or longer was less in the only M1 group
(73.33 %) than in M1/M2 (81.82 %) or only M2 (77.8 %)
groups. Only one CFS case had moderate to severe de-
pression (Zung score >60), and both methods classified
this participant as CFS.
Table 5 summarizes the percentages of CFS cases in
each of the three groups that met each of the MFI-20,
SF-36 and Symptom Inventory thresholds used in
Method 2. For the fatigue criterion, a higher percentage
of those in the M1/M2 and only M2 CFS groups met
the General Fatigue cutoff than those in the only M1
group (95.45, 96.3 and 60 % respectively). A linear
decreasing trend was observed in the percentage of
individuals meeting the Physical Functioning cutoff,
with the only M1 group having the lowest percentage
of all three groups (72.73, 51.85, and 20 %, respect-
ively). The only M1 group also had a much smaller per-
centage of individuals meeting the cutoff for Role
Physical and Social Functioning. The proportion of
those meeting the Role Emotional criterion did not dif-
fer between only M1 and only M2 groups. No instance
in which the SF-36 criterion was fulfilled by meeting
only the Role Emotional cutoff was observed in any
group. Only 33.3 % of the only M1 group had CFS
symptom summary score of ≥25, whereas this was a re-
quirement for M2, so 100 % of those in M1/M2 and
only M2 groups met this criterion. Memory or concen-
tration problems lasting for six months or longer were
less frequent in individuals in the only M2 group
(25.93 %), compared to those in M1/M2 (56.82 %) and
only M1 (46.67 %) groups.
Table 4 Comparison of CFS Cases identified with Two Methods of Applying the 1994 Case Definition
CFS Classification (non-overlapping categories)
Both Methods Method 1 Only Method 2 Only
(n=44; M1/M2) (n=15, only M1) (n=27; only M2)
MFI-20
General Fatigue b, c 17.05 (0.35) 14.20 (0.89) 16.59 (0.46)
Reduced Activity a 12.95 (0.66) 10.27 (1.02) 10.56 (0.66)
Physical Fatigue a, b 14.89 (0.41) 11.67 (1.04) 12.19 (0.70)
Mental Fatigue 13.36 (0.67) 12.47 (1.18) 11.33 (0.69)
Reduced Motivation 12.84 (0.56) 10.47 (0.94) 11.56 (0.65)
SF-36
Physical Functioning c 58.64 (3.47) 78.67 (4.77) 64.81 (5.14)
Role Physical c 31.25 (5.92) 71.67 (7.66) 42.59 (7.76)
Social Functioning c 45.17 (3.28) 70.83 (5.41) 55.09 (3.96)
Role Emotional 46.21 (6.52) 75.55 (8.89) 70.37 (7.82)
Bodily Pain a, b, c 35.20 (2.38) 60.20 (4.58) 46.67 (3.37)
General Health a, b 39.59 (2.63) 66.00 (4.58) 52.48 (3.52)
Vitality b 20.80 (1.93) 36.33 (4.59) 27.41 (3.37)
Mental Health b 55.55 (3.26) 75.73 (4.56) 65.19 (3.83)
CDC SI
Number of CFS Symptoms a, b 5.55 (0.19) 4.6 (0.19) 4.74 (0.13)
CFS Symptom Summary Score a, b, c 48.84 (2.22) 23.23 (2.02) 40.35 (1.94)
PEM in CDC SId, n (%) 36 (81.82%) 11 (73.33%) 21 (77.78%)
Depression
Zung SDS Scoreb 46.48 (1.17) 37.20 (2.02) 42.00 (1.35)
Depression (mod – severe), n (%) 1 (2.27%) 0 0
Sample mean was listed for each group and standard error of mean (SEM) was listed in parenthesis unless otherwise noted. Bonferroni correction was used for
the p-value adjustment for the multiple group comparison
Bold font indicates the subscales used by Method 2 in establishing criteria for 1994 Case Definition
a Significant difference between M1/M2 and only M2
b Significant difference between M1/M2 and only M1
c Significant difference between only M1 and only M2
d PEM = Score ≥ 7.5 for post-exertional fatigue symptom in CDC SI
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Differences between the groups were also highlighted
by the total number of MFI-20, SF-36 and symptom
criteria that were met, eight maximum (Table 5). Sur-
prisingly, only 33 % of those in the only M1 group had
four or more case defining symptoms above threshold
in SI score. Although there were participants in M1/
M2 and only M2 groups that met all eight scoring cut-
offs (36.36 and 11.11 %, respectively), none in the only
M1 group met all eight.
Discussion
The present study indicates that even when using the
same case definition and the same study sample, me-
thods of applying the case definition can impact CFS
classification. We applied the 1994 case definition of
CFS using direct questions to address case definition cri-
teria (Method 1) as well as a method based on the use of
questionnaires with subscale score thresholds for each
dimension (Method 2). While some differences were
noted, classification based on each method showed sub-
stantial agreement (kappa = 0.63 and overall concord-
ance 91.6 %).
Method 2 identified more participants as meeting the
1994 case definition of CFS than did Method 1 (71 com-
pared with 59). This could occur if Method 2 is less spe-
cific or more sensitive than Method 1. In the absence of
a gold standard for true classification, standardized in-
struments measuring fatigue (MFI-20), function (SF-36),
and symptom frequency and severity (CDC-SI) allow
direct comparison of participants classified by either
method alone or by both methods. Differences between
the methods are highlighted by comparing these mea-
sures in participants classified as CFS by only one
method. Individuals classified as CFS only by Method 2
(only M2 group) have significantly higher scores in
General Fatigue, significantly lower scores in Physical
Table 5 MFI, SF-36 and Symptom Inventory Criteria for CFS - Comparison of CFS Cases identified with Two Methods of Applying
the 1994 Case Definition
CFS Classification (non-overlapping categories)
Criteria Both Methods Method 1 Only Method 2 Only
(n=44; M1/M2) (n=15; only M1) (n=27; only M2)
(1) MFI Criterion (one of two cutoffs)
(i) General Fatigue ≥ 13* 42 (95.45 %) 9 (60.00 %) 26 (96.30 %)
(ii) Reduced Activity ≥ 10 34 (77.27 %) 7 (46.67 %) 18 (66.67 %)
Met at least one* 44 (100 %) 11 (73.33 %) 27 (100 %)
(2) SF-36 Criterion (one of four cutoffs)
(iii) Physical Functioning ≤ 70* 32 (72.73 %) 3 (20.00 %) 14 (51.85 %)
(iv) Role Physical ≤ 50* 33 (75.00 %) 4 (26.67 %) 19 (70.37 %)
(v) Social Functioning ≤ 75* 42 (95.45 %) 11 (73.33 %) 25 (92.59 %)
(vi) Role Emotional ≤ 66.67 29 (65.91 %) 6 (40.00 %) 11 (40.74 %)
Met at least one* 44 (100 %) 11 (73.33 %) 27 (100 %)
(3) CDC Symptom Criterion (Both cutoffs)
(vii) ≥ 4 CFS Symptoms lasting ≥ 6 months 44 (100 %) 15 (100 %) 27 (100 %)
(viii) Summary Score ≥ 25* 44 (100 %) 5 (33.33 %) 27 (100 %)
Met both 44 (100 %) 5 (33.33 %) 27 (100 %)
Meet all criteria (1),(2), (3) 44 (100 %) 0 27 (100 %)
Meets SF-36 Criterion based on Role Emotional Alone 0 0 0
Total number of criteria (i)-(viii) met (8 maximum)
1 1 (6.67 %)
2 1 (6.67 %)
3 3 (20.00 %)
4 2 (4.55 %) 5 (33.33 %) 1 (3.70 %)
5 7 (15.91 %) 3 (20.00 %) 7 (25.93 %)
6 4 (9.09 %) 1 (6.67 %) 8 (29.63 %)
7 15 (34.09 %) 1 (6.67 %) 8 (29.63 %)
8 16 (36.36 %) 0 3 (11.11 %)
* indicates p-values < 0.05 for χ2 testing of the independence across three groups
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Functioning, Role Physical, and Social Functioning, and
significantly higher symptom summary score than those
only identified with Method 1 (only M1). In all other
MFI-20, SF-36, and CDC SI measures the two groups
did not differ. This provides assurance that Method 2
does not identify a population that is less severely
affected. Individuals classified as CFS by both methods
(M1/M2 group) were in general more fatigued, had
more functional impairment, more CFS symptoms, and
higher CFS symptom summary scores compared to
those in the only M1 or only M2 groups. Additionally,
Method 2 includes the threshold of 25 for the CFS
symptom summary scores, enabling better quantifying of
CFS symptom severity as a whole. About 67 % of those
identified only with Method 1 failed to exceed this
symptom severity threshold.
Inclusion of the SF-36 Role Emotional score as one
option to meet the functional impairment criterion has
led to criticism that Method 2 could identify individuals
with major depressive disorder (MDD) rather than CFS
[21]. In fact, none of those identified as CFS by any
method met the functional impairment criterion based
only on Role Emotional (Table 5). Only one CFS patient
(identified by both methods) had moderate to severe de-
pression (Zung ≥60). All three groups had higher mental
health SF-36 scores (55.55 for M1/M2, 65.19 for only
M2, and 75.73 for only M1) and role emotional func-
tioning (46.21 for M1/M2, 70.37 for only M2, and 75.55
for only M1) than the SF-36 norms observed among
patients with depression in outpatient clinics (36.37
and 38.60, respectively; [28]). However, the mean
scores for Vitality (an estimate of vitality, energy, and
fatigue) for those classified by both methods (20.80)
and those by Method 2 only (27.41) were much lower
than the mean score reported for depressive patients
(39.91) [28].
While the present study focuses on the use of ques-
tionnaires to establish minimal criteria for case ascer-
tainment in a population-based surveillance study, it is
clear that the instruments provide additional value by
providing measures of illness that can be used to stratify
or subgroup CFS. The questionnaires could serve as pa-
tient/person reported outcome measures to describe the
natural history of the illness, identify and quantify
change in response to interventions, and provide criteria
to identify patient populations with similar characteris-
tics for basic research and clinical trials. As shown by
the above comparisons, these instruments allow direct
comparison of illness severity between groups, as well as
between persons with CFS and other illnesses. Further
studies designed to establish the reliability and validity
of each of these instruments for CFS and other illnesses,
as well as to identify clinically meaningful changes, are
needed.
The study design included rigorous screening includ-
ing clinical, laboratory, and psychological evaluation
(including SCID) to identify exclusionary medical and
psychiatric conditions. In the absence of this screening
process, both methods of applying the 1994 case defin-
ition could identify a very different sample. Failure to
screen for exclusionary conditions prior to using the
Method 2 algorithm may explain the perception that it
generates significant classification errors [21].
While the current analysis provides reassurance that
the 10-fold difference in the population- based preva-
lence estimates in the 1997 Wichita and 2004 Georgia
studies [18, 19] is not due to inclusion of those with psy-
chiatric illnesses or those less severely affected, it does
not explain the prevalence difference. The increased de-
tection with Method 2 compared to Method 1 does not
fully explain the difference in prevalence. Other differ-
ences in study design, such as the initial household
screening based on fatigue, pain, cognition, and sleep
rather than restricting to fatigue, restricted age of en-
rollment (18–59 years), match criteria, and weighting
of estimates undoubtedly contributed to the different
prevalence estimates between the two studies. The
Georgia study identified more participants as eligible
for clinic evaluation because fewer exclusions were
based on information provided in the telephone
interviews.
Further work needs to be done to evaluate the impact
of using different cut-off values for each criterion as well
as using other standardized instruments to measure the
illness domains of CFS. Instruments that have been
rigorously validated in general populations and therefore
have established general population norms, such as the
SF-36 and MFI-20, may not capture all aspects of func-
tion and fatigue in CFS. While one study did evaluate
MFI-20 in CFS [30], a recent review of available measures
of CFS indicates that few have been used in more than
one study and evaluation of instrument performance
needs improvement [31]. In addition, using instruments
such as those developed by the NIH Patient Reported
Outcomes Measurement Information System (PROMIS)
initiative (http://www.nihpromis.org/about/overview) for
application in a wide variety of chronic diseases and
conditions will allow direct comparison of CFS to other
conditions.
Changes in the CFS case definition would require
different algorithms and different approaches to
operationalize them for research. Most definitions
recognize the same domains of illness but vary in the
number of required symptoms. Another advantage of
using standardized instruments to operationalize the
case definition for research studies is that participants
could be reclassified and stratified depending on the
needs of the study.
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Conclusions
Even when using the same CFS case definition, methods
of applying the case definition influence case ascertain-
ment with subsequent impact on observed disease
prevalence and severity. Research studies of CFS pa-
tients need to specify both the case definition and the
specific approach and tools or instruments used to
apply the definition. Use of standardized instruments
for the major domains of CFS such as fatigue (MFI-20),
functional impairment (SF-36), and symptoms (CDC-SI)
has advantages for ascertainment, disease stratification,
and comparing CFS patients to other illnesses. The IOM
report on ME/CFS recommended clinical evaluation of
these and other standardized instruments. Further studies
are needed to optimize thresholds for criterion identifica-
tion and to validate clinically meaningful changes in
scores.
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